An analyst from Redburn Partners has set a $127 price target for Abbott Laboratories, indicating a 31.3% upside from its recent price of around $96.71. Despite a recent decline in Abbott's stock, the company expects strong quarterly earnings of $1.43 per share and revenue growth to $12.91 billion. Abbott is also expanding its colorectal cancer screening portfolio with a new FDA-approved blood test, SimpleScreen CRC, targeting millions of Americans due for screening. The upcoming earnings report on October 21 will be key for investors to assess the company's performance against this optimistic outlook.
Ahead of Abbott Laboratories' upcoming earnings report, its stock is trading at USD 97.51 on Pluang as of Oct 02, 2026 20:15 WIB, showing a modest 0.83% gain for the day. The stock's market cap stands at $167.31 billion, with a dividend yield of 2.55%. Despite the positive analyst outlook, Pluang data shows that 84% of order activity is selling, indicating cautious investor sentiment.
Abbott will announce its financial results for the third quarter of 2026 on October 21 before the market opens. The company will host a live webcast of the earnings conference call at 8 a.m. Central time, accessible via Abbott's Investor Relations we...
Abbott has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in adults aged 45 and older at average risk. This test offers a convenient alternative for those who decline or do not complete stool-based or visual scr...
Abbott Laboratories, Medtronic, and Becton Dickinson, three leading medical device companies, have each increased their dividends recently, continuing long streaks of annual raises—54 years for Abbott, 49 for Medtronic, and consistent growth for Bect...
